Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection
Guardant Health (Nasdaq: GH) announced its Shield™ multi-cancer detection (MCD) test has been selected by the National Cancer Institute (NCI) for inclusion in the Vanguard study. The selection was based on the platform's strong performance in detecting various cancer types and predicting cancer tissue origin.
The Vanguard study is a four-year pilot initiative by the NCI's Cancer Screening Research Network (CSRN) that will enroll up to 24,000 people to inform the design of a larger randomized controlled trial evaluating MCD tests for cancer screening. Guardant Health was chosen as one of only two participants after evaluation of multiple companies.
The study will assess the Shield platform's performance in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric cancers. Results from the NCI verification study are expected in early 2025.
Guardant Health (Nasdaq: GH) ha annunciato che il suo test di rilevazione multipla del cancro (MCD) Shield™ è stato selezionato dal National Cancer Institute (NCI) per essere incluso nello studio Vanguard. La selezione si basa sull'eccellente performance della piattaforma nella rilevazione di vari tipi di cancro e nella previsione dell'origine del tessuto canceroso.
Lo studio Vanguard è un'iniziativa pilota di quattro anni della rete di ricerca sullo screening dei tumori (CSRN) dell'NCI, che arruolerà fino a 24.000 persone per informare la progettazione di un trial controllato randomizzato più ampio che valuta i test MCD per lo screening del cancro. Guardant Health è stata scelta come uno dei soli due partecipanti dopo la valutazione di diverse aziende.
Lo studio valuterà le performance della piattaforma Shield nella rilevazione di 10 tipi di cancro, inclusi i tumori polmonari, mammari, colorettali, prostatici, vescicali, ovarici, pancreatici, esofagei, epatici e gastrici. I risultati dello studio di verifica dell'NCI sono attesi all'inizio del 2025.
Guardant Health (Nasdaq: GH) anunció que su prueba de detección múltiple de cáncer (MCD) Shield™ ha sido seleccionada por el Instituto Nacional del Cáncer (NCI) para su inclusión en el estudio Vanguard. La selección se basó en el fuerte rendimiento de la plataforma en la detección de varios tipos de cáncer y en la predicción del origen del tejido canceroso.
El estudio Vanguard es una iniciativa piloto de cuatro años de la Red de Investigación en Detección del Cáncer (CSRN) del NCI, que inscribirá hasta 24,000 personas para informar el diseño de un ensayo controlado aleatorio más amplio que evalúe las pruebas de MCD para la detección de cáncer. Guardant Health fue elegida como uno de solo dos participantes después de la evaluación de múltiples empresas.
El estudio evaluará el rendimiento de la plataforma Shield en la detección de 10 tipos de cáncer, incluidos los cánceres de pulmón, mama, colorrectal, próstata, vejiga, ovario, páncreas, esófago, hígado y estómago. Se esperan los resultados del estudio de verificación del NCI a principios de 2025.
가드란트 헬스 (Nasdaq: GH)는 자사의 다중 암 검출(MCD) 테스트인 Shield™가 국립암연구소(NCI)에 의해 밴가드 연구에 포함되기로 선정되었다고 발표했습니다. 선정은 다양한 유형의 암을 검출하고 암 조직의 기원을 예측하는 데 있어 플랫폼의 강력한 성능에 기반하고 있습니다.
밴가드 연구는 NCI의 암 선별 연구 네트워크(CSRN)가 주관하는 4년 간의 파일럿 이니셔티브로, 최대 24,000명을 등록하여 MCD 테스트의 암 선별 평가를 위한 더 큰 무작위 대조 시험 설계를 안내할 것입니다. 여러 회사를 평가한 결과 가드란트 헬스는 두 개의 참가자 중 하나로 선택되었습니다.
이 연구는 Shield 플랫폼이 10종의 암을 검출하는 성능을 평가할 것이며, 여기에는 폐, 유방, 대장, 전립선, 방광, 난소, 췌장, 식도, 간 및 위암이 포함됩니다. NCI 검증 연구의 결과는 2025년 초에 발표될 예정입니다.
Guardant Health (Nasdaq: GH) a annoncé que son test de détection multifactoriel du cancer (MCD) Shield™ a été sélectionné par l'Institut national du cancer (NCI) pour inclusion dans l'étude Vanguard. Cette sélection a été fondée sur la solide performance de la plateforme dans la détection de divers types de cancer et dans la prédiction de l'origine des tissus cancéreux.
L'étude Vanguard est une initiative pilote de quatre ans menée par le réseau de recherche sur le dépistage du cancer (CSRN) de l'NCI, qui recrutera jusqu'à 24 000 personnes afin d'informer la conception d'un essai clinique contrôlé randomisé plus vaste évaluant les tests MCD pour le dépistage du cancer. Guardant Health a été choisi comme l'un des deux seuls participants après l'évaluation de plusieurs entreprises.
Cette étude évaluera la performance de la plateforme Shield dans la détection de 10 types de cancer, y compris les cancers du poumon, du sein, colorectal, de la prostate, de la vessie, des ovaires, du pancréas, de l'œsophage, du foie et de l'estomac. Les résultats de l'étude de vérification de l'NCI sont attendus début 2025.
Guardant Health (Nasdaq: GH) gab bekannt, dass sein Shield™ Multi-Cancer Detection (MCD) Test vom National Cancer Institute (NCI) für die Teilnahme an der Vanguard-Studie ausgewählt wurde. Die Auswahl basierte auf der starken Leistung der Plattform bei der Erkennung verschiedener Krebsarten und der Vorhersage des Ursprungs von Krebsgewebe.
Die Vanguard-Studie ist eine vierjährige Pilotinitiative des NCI's Cancer Screening Research Network (CSRN), die bis zu 24.000 Personen einschreiben wird, um das Design einer umfassenderen randomisierten kontrollierten Studie zur Evaluierung von MCD-Tests für das Krebs-Screening zu informieren. Guardant Health wurde nach der Auswertung mehrerer Unternehmen als einer von nur zwei Teilnehmern ausgewählt.
Die Studie wird die Leistung der Shield-Plattform bei der Erkennung von 10 Krebsarten bewerten, darunter Lungen-, Brust-, Dickdarm-, Prostata-, Blasen-, Eierstock-, Bauchspeicheldrüsen-, Speiseröhren-, Leber- und Magenkrebs. Die Ergebnisse der NCI-Überprüfungsstudie werden Anfang 2025 erwartet.
- Selected as one of only two companies for NCI's Vanguard study
- Platform demonstrated strong performance in detecting 10 different cancer types
- Participation in large-scale study with 24,000 participants enhances market validation
- Results from NCI verification study not available until early 2025
- Commercial success dependent on future larger trial outcomes
Insights
The selection of Guardant Health's Shield platform for the NCI's Vanguard study represents a major validation of their multi-cancer detection technology. Being chosen as one of only two participants from multiple competitors highlights the platform's superior performance characteristics. The study's scope of 24,000 participants and 10 cancer types is particularly comprehensive.
The inclusion in this pilot study positions Guardant Health strategically for potential participation in larger future trials. This is especially significant as it could accelerate the pathway to broader clinical adoption and eventual reimbursement coverage. The focus on underserved populations also aligns with current healthcare initiatives and could expand market access.
Think of this like being selected for an elite Olympic training camp - it doesn't guarantee future success, but it validates the technology's potential and provides a pathway to larger opportunities. The early 2025 timeline for results publication could serve as a near-term catalyst for the stock.
This development significantly strengthens Guardant Health's position in the rapidly growing liquid biopsy market, estimated to reach
The four-year pilot study duration provides a steady stream of data and potential catalysts. If successful, this could lead to inclusion in larger trials and eventually standard screening protocols, representing a substantial market opportunity. The focus on diverse populations also positions the company well for broad market adoption and potential government contracts.
The Shield platform's selection validates Guardant's R&D investments and could accelerate partnership opportunities with healthcare providers and insurers. This is particularly relevant given the growing emphasis on preventive care and early cancer detection in healthcare systems globally.
- Guardant Health Shield multi-cancer detection test selected on basis of strong performance in predicting presence of cancers and cancer tissue of origin
- Pilot study by National Cancer Institute’s Cancer Screening Research Network will inform design of future research evaluating use of multi-cancer detection blood tests to screen for cancer
In February 2024, the National Institutes of Health (NIH) launched the Cancer Screening Research Network (CSRN), which is funded by the NCI, part of NIH, to evaluate emerging cancer screening technologies, including MCD tests. The network will support research to investigate how to identify and diagnose cancers earlier, when they may be easier to treat.
As an initial effort, CSRN is launching the Vanguard Study, a four-year pilot study that will enroll up to 24,000 people to inform the design of a much larger randomized controlled trial evaluating the use of MCD tests for cancer screening. In its studies, the network aims to reach diverse populations, including underserved populations, that are receiving routine care in a variety of health care settings.
“Despite recent advances in screening technology, there are still many types of cancer that are difficult to detect with existing technologies until the late stages, when they become much more challenging to treat,” said AmirAli Talasaz, Guardant Health co-CEO. “We are excited about the potential for early detection of multiple cancers through a simple blood draw with our Shield MCD test. The Vanguard study is an important step in demonstrating the value of our technology.”
Of the many companies whose tests were evaluated by NCI to be considered for inclusion in the Vanguard study, Guardant Health was selected to be one of two participants, based on the overall performance of its Shield platform. The NCI provided a blinded reference set to verify the platform’s performance in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. Results from the NCI verification study are expected to be published in early 2025.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107905482/en/
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Michael Weist
press@guardanthealth.com
+1 317-371-0035
Source: Guardant Health, Inc.
FAQ
What is the significance of GH's Shield platform being selected for the NCI Vanguard study?
How many cancer types can Guardant Health's Shield MCD test detect?
When will the NCI verification study results for GH's Shield platform be published?
What is the duration and size of the Vanguard study involving GH's Shield platform?
How does GH's Shield platform detect multiple cancers?
